Literature DB >> 1980236

Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism.

D T Nash1.   

Abstract

The sympathetic nervous system plays a major role in the pathogenesis of essential hypertension and is mediated by the alpha and beta receptors. The alpha receptor is divided into two types, alpha 1 and alpha 2, based on response to epinephrine and norepinephrine. alpha 1-Adrenergic receptors have a high affinity for drugs such as prazosin, doxazosin, and terazosin, which act to reduce blood pressure by selective blockade of the receptor. These agents provide a rational approach to the treatment of hypertension by correcting elevated total peripheral resistance, the fundamental hemodynamic abnormality in essential hypertension. In contrast, early alpha-adrenergic receptor blockers nonselectively blocked both alpha 1 and alpha 2 receptors and were unsuitable as antihypertensive agents because they induced tachycardia and patients developed a tolerance to them rapidly. alpha 1-Adrenergic blockers also have beneficial effects on plasma lipoproteins, tending to decrease levels of triglycerides and cholesterol and increase levels of high-density lipoprotein (HDL) cholesterol and the HDL cholesterol/total cholesterol ratio. beta-Adrenergic blockers, such as propranolol and atenolol, have been shown to have an adverse effect on the lipid profile by tending to increase levels of triglycerides and decrease HDL cholesterol. A number of mechanisms contribute to these effects, in particular, adrenergic modulation of lipoprotein lipase and the triglyceride secretion rate. Doxazosin has been shown to increase the activity of LDL receptors, which may be partly responsible for its beneficial effect on plasma lipids and lipoproteins.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980236     DOI: 10.1002/clc.4960131104

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  13 in total

Review 1.  The role of the kidney and the sympathetic nervous system in hypertension.

Authors:  Philip Thomas; Indranil Dasgupta
Journal:  Pediatr Nephrol       Date:  2014-03-08       Impact factor: 3.714

2.  Metabolic effects of prazosin on skeletal muscle insulin resistance in glucocorticoid-treated male rats.

Authors:  Emily C Dunford; Erin R Mandel; Sepideh Mohajeri; Tara L Haas; Michael C Riddell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-09       Impact factor: 3.619

Review 3.  Pharmacologic Treatment of Pediatric Hypertension.

Authors:  Rachita S Dhull; Rossana Baracco; Amrish Jain; Tej K Mattoo
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

4.  The Specific α1-Adrenergic Receptor Antagonist Prazosin Influences the Urine Proteome.

Authors:  Mindi Zhao; Jianqiang Wu; Youhe Gao
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

5.  Blood flow controls bone vascular function and osteogenesis.

Authors:  Saravana K Ramasamy; Anjali P Kusumbe; Maria Schiller; Dagmar Zeuschner; M Gabriele Bixel; Carlo Milia; Jaba Gamrekelashvili; Anne Limbourg; Alexander Medvinsky; Massimo M Santoro; Florian P Limbourg; Ralf H Adams
Journal:  Nat Commun       Date:  2016-12-06       Impact factor: 14.919

6.  Pulsation-limited oxygen diffusion in the tumour microenvironment.

Authors:  Edoardo Milotti; Sabrina Stella; Roberto Chignola
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

7.  The effect of epinephrine on the perfusion index during ultrasound-guided supraclavicular brachial plexus block: a randomized controlled trial.

Authors:  Doyeon Kim; Ji Seon Jeong; Min Jong Park; Justin Sangwook Ko
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

8.  Angiocrine signals regulate quiescence and therapy resistance in bone metastasis.

Authors:  Amit Singh; Vimal Veeriah; Pengjun Xi; Rossella Labella; Junyu Chen; Sara G Romeo; Saravana K Ramasamy; Anjali P Kusumbe
Journal:  JCI Insight       Date:  2019-07-11

9.  Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects.

Authors:  Nora E Straznicky; Elisabeth A Lambert; Paul J Nestel; Mariee T McGrane; Tye Dawood; Markus P Schlaich; Kazuko Masuo; Nina Eikelis; Barbora de Courten; Justin A Mariani; Murray D Esler; Florentia Socratous; Reena Chopra; Carolina I Sari; Eldho Paul; Gavin W Lambert
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

10.  Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.

Authors:  Steven T Bird; Joseph A C Delaney; James M Brophy; Mahyar Etminan; Sean C Skeldon; Abraham G Hartzema
Journal:  BMJ       Date:  2013-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.